Sign In
Buy ZYME
$24.35
+0.240 (+1.00%)
At Close: Jun 03, 2026
Zymeworks Inc. $ZYME Shares Purchased by Assenagon Asset Management S.A.
03:26am, Saturday, 20'th Dec 2025
Assenagon Asset Management S.A. raised its stake in Zymeworks Inc. (NYSE: ZYME) by 169.2% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,326,774 share
Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of “Buy” from Brokerages
01:16am, Saturday, 13'th Dec 2025
Shares of Zymeworks Inc. (NYSE: ZYME - Get Free Report) have earned an average recommendation of "Buy" from the ten brokerages that are covering the stock, Marketbeat reports. Ten investment analysts
Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
11:23pm, Wednesday, 03'rd Dec 2025
Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Zymeworks Announces Participation in Upcoming Conferences
04:05pm, Tuesday, 02'nd Dec 2025
• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera ® across HER2-driven gastrointestinal cancers by partner Jazz • Zymeworks to present a
Critical Review: Acerus Pharmaceuticals (OTCMKTS:ASPCF) vs. Zymeworks (NASDAQ:ZYME)
02:30am, Tuesday, 02'nd Dec 2025
Acerus Pharmaceuticals (OTCMKTS:ASPCF - Get Free Report) and Zymeworks (NASDAQ: ZYME - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the tw
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Monday, 24'th Nov 2025
VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipe
Zymeworks: Adjusting My Levels After Ziihera's Phase III Data For GEA
09:11am, Friday, 21'st Nov 2025
Zymeworks is gaining momentum as Ziihera shows strong Phase III data in HER2+ gastroesophageal adenocarcinoma, supporting growth and de-risking the investment. ZYME's royalty-based business model with
Zymeworks: A Lot Of Moving Parts
02:10pm, Wednesday, 19'th Nov 2025
This article revisits Zymeworks Inc. following significant new trial data released this week. This triggered a 30% rally in ZYME stock on Monday, even as most of any future revenues will accrue to par
Zymeworks Inc. (ZYME) Shareholder/Analyst Call Transcript
05:08pm, Tuesday, 18'th Nov 2025
Zymeworks Inc. ( ZYME ) Shareholder/Analyst Call November 18, 2025 8:30 AM EST Company Participants Shrinal Inamdar - Director of Investor Relations Kenneth Galbraith - Chairman of the Board, CEO & Pr
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
01:01am, Tuesday, 18'th Nov 2025
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pip
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipe
Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise
02:43pm, Monday, 17'th Nov 2025
Jazz Pharmaceuticals plc and Zymeworks Inc. announced positive topline phase 3 results for Ziihera in HER2-positive gastroesophageal adenocarcinoma. Ziihera in combination with chemotherapy and in com
Zymeworks Surges On Positive Ziihera Phase 3 Data: Expanding First-Line GEA Opportunity
01:45pm, Monday, 17'th Nov 2025
Zymeworks Inc. (ZYME) surged after positive Phase 3 results for Ziihera in first-line HER2-positive gastroesophageal adenocarcinoma, expanding its FDA-approved indications. ZYME's partnership-driven m
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans
12:09pm, Monday, 17'th Nov 2025
Zymeworks Inc. (NASDAQ: ZYME) stock is surging on Monday, with a session volume of 2.17 million, compared to an average volume of 728.75K, according to Benzinga Pro.
Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.
08:10am, Monday, 17'th Nov 2025
The companies' drug Ziihera shows clinically meaningful benefits for patients with gastroesophageal adenocarcinoma.
